Ophthalmologists in the United States can order the Lucentis 0.3 mg prefilled syringe (PFS). The PFS was approved on March 21, 2018 as a new method of administering the medicine to treat all forms of diabetic retinopathy, with or without diabetic macular edema (DME).
Ophthalmologists in the US now have the option to order an FDA-approved prefilled syringe for all Lucentis indications: the 0.3 mg dose to treat diabetic retinopathy and DME, and the 0.5 mg dose to treat wet age-related macular degeneration (AMD), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV).
The Lucentis 0.3 mg PFS, which is made of borosilicate glass and is packaged in a single-use sterile, sealed tray, allows physicians to eliminate several steps in the preparation and administration process, including disinfecting the vial, attaching a filter needle, drawing the medicine from the vial using the needle, removing the filter needle from the syringe and replacing with an injection needle. With the Lucentis PFS, physicians snap off the syringe cap, attach the injection needle to the syringe and adjust the dose prior to administration.
Lucentis remains the only medicine FDA-approved to treat all forms of diabetic retinopathy, and is the first syringe prefilled with an anti-vascular endothelial growth factor (VEGF) agent approved to treat five retinal conditions, according to Genentech.